

# LUNG-TARGETING NANOBODIES

UNM TECH NAVIGATOR CHALLENGE 2025

PRESENTED BY:

Myah Rupley and Beliza Sanchez

**NanoLung**

**262.4 MILLION**

**Asthma diagnoses worldwide**


**212.3 MILLION**

**Chronic Pulmonary Disease (COPD) diagnoses worldwide**

# Problem

## Current Medications on the Market


**01** Slow to act



**02** Costly




**03** Numerous side effects




# Solution

We are developing a novel drug delivery system using lung-targeting nanobodies. These small, highly specific antibody-like molecules are engineered to target therapeutic agents directly to the lungs, improving the drug's efficacy while minimizing side effects.



# Product




Nanobodies can be conjugated with bronchodilators, anti-inflammatory drugs, or biologics to treat asthma and COPD




# Market Opportunity

## Respiratory Care Market Evaluation




- Market for targeted therapies is expanding.
- Opportunity to capitalize on the trend toward increasing drug efficacy and minimizing side effects.
- Benefit massive patient population.

# Challenges



Market Adoption

Demonstrate clear clinical efficacy and cost-benefit advantages.




Patient Adoption

Familiar inhalation method, making patient transition simple and intuitive.



FDA Regulatory Hurdles

Early regulatory consultation and leverage existing guidelines.



# Channels

## Clinical Trials

- Phase I
- Phase II
- Phase III



**Regulatory  
Approval**



**Partnerships  
for  
Distribution**



**Physicians**



**Patients**



# Partners

## Pharmaceutical Companies



## Research Institutions



## Contract Manufacturing Organizations






# Competition

	NanoLung	Existing Inhalers and Nebulizers	Novel Targeted Therapies	Existing Oral Medications
Reduced Drug Dosage and Frequency	✓			
Precise Targeting	✓		✓	
Reduced Side Effects	✓		✓	
Cost Effective	✓	✓		✓


# Raising Capital




## Why Invest?

- Various avenues of income
- Lower manufacturing costs = higher profit margins
- Reduced dosing frequency which reduces healthcare costs and benefits insurers.

# Next Steps



# Our team



**Myah Rupley**

Undergrad  
BS Environmental  
Science



**Beliza Sanchez**

Undergrad  
BS Public Health